Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RPT193 · 1 trial · 1 indication
Number of participants with abnormal laboratory values and/or adverse events that are related to treatment
| Arm | Type | Description |
|---|---|---|
| COMPLETED ENROLLMENT -- Single Dose Escalation Part A - active | EXPERIMENTAL | Increasing doses of RPT193 will be administered to healthy volunteers |
| COMPLETED ENROLLMENT -- Single Dose Escalation Part A - placebo | PLACEBO_COMPARATOR | Matching placebo will be administered to healthy volunteers |
| COMPLETED ENROLLMENT -- Multiple Dose Escalation Part B - active | EXPERIMENTAL | Increasing doses of RPT193 will be administered once/day for 7 days to healthy volunteers |
| COMPLETED ENROLLMENT -- Multiple Dose Escalation Part B - placebo | PLACEBO_COMPARATOR | Matching placebo will be administered once/day for 7 days to healthy volunteers |
| COMPLETED ENROLLMENT -- Expansion Part C - active | EXPERIMENTAL | RPT193 will be administered daily for 28 days to patients with atopic dermatitis |
| COMPLETED ENROLLMENT -- Expansion Part C - placebo | PLACEBO_COMPARATOR | Matching placebo will be administered daily for 28 days to patients with atopic dermatitis |
| Name | Type | Description |
|---|---|---|
| RPT193 | DRUG | Antagonist of the CCR4 chemokine receptor |
| Placebo | DRUG | Matching placebo |
Selected Inclusion Criteria: Parts A \& B (COMPLETED ENROLLMENT): * Healthy male or female * 18-55 years of age, inclusive * At least 50 kg in weight * BMI: 18.0-30.0 kg/m2, inclusive Part C (COMPLETED ENROLLMENT): * Male or female with atopic dermatitis * 18-65 years of age, inclusive * BMI bet...
Top 20 of 26 competitors
RPT193 is an investigational small molecule being developed for the treatment of atopic dermatitis, a chronic inflammatory skin condition. It is in Phase 1 clinical development and has not been approved for any indication. RAPT Therapeutics, Inc. is the developer.
RPT193 targets CCR4, a chemokine receptor. By binding to CCR4, the drug is designed to modulate immune cell trafficking, which may reduce inflammation associated with atopic dermatitis. This mechanism is being evaluated in clinical trials.
RPT193 is being developed by RAPT Therapeutics, Inc., a biopharmaceutical company. The company's ticker symbol is RAPT. RAPT Therapeutics is focused on discovering and developing oral small molecule therapies for inflammatory diseases and oncology.
RPT193 is in Phase 1 clinical development. It has completed one Phase 1 trial and is not currently in active trials. The drug remains investigational and has not been approved by the FDA or any regulatory agency.
RPT193 has been evaluated in a single Phase 1 trial, NCT04271514, titled 'A First-in-Human Study of RPT193 in Healthy Volunteers and Patients With Atopic Dermatitis.' The trial was completed and enrolled 103 participants across the United States and the Netherlands.
No, RPT193 is not approved by the FDA. It is an investigational drug in Phase 1 clinical development for atopic dermatitis. Approval would require successful completion of later-stage trials and regulatory review.